Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) kicked off on Tuesday, up 0.58% from the previous trading day, before settling in for the closing price of $43.12. Over the past 52 weeks, CRNX has traded in a range of $15.23-$47.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 64.83%. While this was happening, its average annual earnings per share was recorded 13.21%. With a float of $71.17 million, this company’s outstanding shares have now reached $77.93 million.
Considering the fact that the conglomerate employs 290 people, you should pay attention to its efficiency factor.
Crinetics Pharmaceuticals Inc (CRNX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Crinetics Pharmaceuticals Inc is 8.67%, while institutional ownership is 89.58%. The most recent insider transaction that took place on Mar 22 ’24, was worth 1,433,675. In this transaction Chief Operating Officer of this company sold 32,359 shares at a rate of $44.31, taking the stock ownership to the 52,580 shares. Before that another transaction happened on Mar 20 ’24, when Company’s Director sold 60,000 for $44.14, making the entire transaction worth $2,648,150. This insider now owns 18,536 shares in total.
Crinetics Pharmaceuticals Inc (CRNX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/30/2023, the organization reported -$0.9 earnings per share (EPS), lower than consensus estimate (set at -$0.86) by -$0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.21% per share during the next fiscal year.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Take a look at Crinetics Pharmaceuticals Inc’s (CRNX) current performance indicators. Last quarter, stock had a quick ratio of 13.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.70, a number that is poised to hit -0.81 in the next quarter and is forecasted to reach -3.54 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Compared to the last year’s volume of 0.75 million, its volume of 0.88 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 66.02%. Additionally, its Average True Range was 2.48.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 80.71%, which indicates a significant increase from 63.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.14% in the past 14 days, which was higher than the 55.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $39.39, while its 200-day Moving Average is $29.09. Nevertheless, the first resistance level for the watch stands at $44.21 in the near term. At $45.04, the stock is likely to face the second major resistance level. The third major resistance level sits at $45.81. If the price goes on to break the first support level at $42.61, it is likely to go to the next support level at $41.84. Now, if the price goes above the second support level, the third support stands at $41.01.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Key Stats
The company with the Market Capitalisation of 3.38 billion has total of 69,600K Shares Outstanding. Its annual sales at the moment are 4,010 K in contrast with the sum of -214,530 K annual income. Company’s last quarter sales were recorded 350 K and last quarter income was -57,460 K.
